Robert Iannone

CIK: 0001737329

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)10 (37.0%)

Position reduction

Option Exercises (M)4 (14.8%)

Derivative conversions

Awards (A)8 (29.6%)

Compensation grants

Other (G, F, J, C, D, …)5 (18.5%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

JAZZ

Jazz Pharmaceuticals plc

Officer

PLRX

PLIANT THERAPEUTICS, INC.

Director

AUTL

Autolus Therapeutics plc

Director

Discretionary Trading P&L

Holdings

Transaction History (27 total)

JAZZ
Jazz Pharmaceuticals plc
Aug 27, 2026
Exercise(M)
Direct
26.1K shares at avg. $113.10$3.0M
JAZZ
Jazz Pharmaceuticals plc
Aug 27, 2026
Sale(S)
Direct
300 shares at avg. $252.76$76K
JAZZ
Jazz Pharmaceuticals plc
Aug 27, 2026
Sale(S)
Direct
9.3K shares at avg. $251.95$2.3M
JAZZ
Jazz Pharmaceuticals plc
Aug 27, 2026
Sale(S)
Direct
19.6K shares at avg. $250.60$4.9M
JAZZ
Jazz Pharmaceuticals plc
Aug 27, 2026
Sale(S)
Direct
18.1K shares at avg. $250.02$4.5M
JAZZ
Jazz Pharmaceuticals plc
Aug 27, 2026
Sale(S)
Direct
11.4K shares at avg. $248.67$2.8M
JAZZ
Jazz Pharmaceuticals plc
Aug 27, 2026
Sale(S)
Direct
18.2K shares at avg. $247.86$4.5M
JAZZ
Jazz Pharmaceuticals plc
Aug 27, 2026
Exercise(M)
Direct
2.9K shares at avg. $137.12$400K
JAZZ
Jazz Pharmaceuticals plc
Aug 27, 2026
Exercise(M)
Direct
27.6K shares at avg. $137.12$3.8M
JAZZ
Jazz Pharmaceuticals plc
Aug 27, 2026
Exercise(M)
Direct
884 shares at avg. $113.10$100K
PLRX
PLIANT THERAPEUTICS, INC.
Jul 9, 2026
Award(A)
Stock Option (Right to Buy)
Direct
60K shares-
JAZZ
Jazz Pharmaceuticals plc
Jun 30, 2026
Tax Payment(F)
Direct
3.8K shares at avg. $237.72$895K
AUTL
Autolus Therapeutics plc
Jun 29, 2026
Award(A)
Share Option (Right to Buy)
Direct
47.5K shares-
AUTL
Autolus Therapeutics plc
Jun 29, 2026
Award(A)
Restricted Share Units
Direct
31.7K shares-
JAZZ
Jazz Pharmaceuticals plc
Mar 5, 2026
Tax Payment(F)
Direct
6.2K shares at avg. $188.69$1.2M
JAZZ
Jazz Pharmaceuticals plc
Feb 26, 2026
Award(A)
Direct
14.8K shares-
JAZZ
Jazz Pharmaceuticals plc
Jan 16, 2026
Award(A)
Direct
11.7K shares-
JAZZ
Jazz Pharmaceuticals plc
Jan 16, 2026
Tax Payment(F)
Direct
4.1K shares at avg. $171.16$709K
JAZZ
Jazz Pharmaceuticals plc
Nov 17, 2025
Sale(S)
Direct
7.2K shares at avg. $168.26$1.2M
JAZZ
Jazz Pharmaceuticals plc
Mar 10, 2025
Sale(S)
Direct
2.4K shares at avg. $138.41$333K
JAZZ
Jazz Pharmaceuticals plc
Mar 7, 2025
Sale(S)
Direct
5.5K shares at avg. $138.21$765K
JAZZ
Jazz Pharmaceuticals plc
Mar 7, 2025
Sale(S)
Direct
1.5K shares at avg. $140.00$217K
JAZZ
Jazz Pharmaceuticals plc
Mar 5, 2025
Disposition(D)
Direct
5.2K shares at avg. $138.95$728K
JAZZ
Jazz Pharmaceuticals plc
Feb 27, 2025
Award(A)
Direct
17.7K shares-
JAZZ
Jazz Pharmaceuticals plc
Feb 27, 2025
Award(A)
Direct
8.9K shares-

		Type	Shares	Price		Ownership
Aug 27, 2026	JAZZ Jazz Pharmaceuticals plc	Exercise(M)	26,116	$113.10	$2,953,720	Direct
Aug 27, 2026	JAZZ Jazz Pharmaceuticals plc	Sale(S)	300	$252.76	$75,828	Direct
Aug 27, 2026	JAZZ Jazz Pharmaceuticals plc	Sale(S)	9,259	$251.95	$2,332,804	Direct
Aug 27, 2026	JAZZ Jazz Pharmaceuticals plc	Sale(S)	19,639	$250.60	$4,921,596	Direct
Aug 27, 2026	JAZZ Jazz Pharmaceuticals plc	Sale(S)	18,113	$250.02	$4,528,572	Direct
Aug 27, 2026	JAZZ Jazz Pharmaceuticals plc	Sale(S)	11,423	$248.67	$2,840,516	Direct
Aug 27, 2026	JAZZ Jazz Pharmaceuticals plc	Sale(S)	18,187	$247.86	$4,507,781	Direct
Aug 27, 2026	JAZZ Jazz Pharmaceuticals plc	Exercise(M)	2,916	$137.12	$399,842	Direct
Aug 27, 2026	JAZZ Jazz Pharmaceuticals plc	Exercise(M)	27,584	$137.12	$3,782,318	Direct
Aug 27, 2026	JAZZ Jazz Pharmaceuticals plc	Exercise(M)	884	$113.10	$99,980	Direct
Jul 9, 2026	PLRX PLIANT THERAPEUTICS, INC.	Award(A) Stock Option (Right to Buy)	60,000	-	-	Direct
Jun 30, 2026	JAZZ Jazz Pharmaceuticals plc	Tax Payment(F)	3,764	$237.72	$894,778	Direct
Jun 29, 2026	AUTL Autolus Therapeutics plc	Award(A) Share Option (Right to Buy)	47,500	-	-	Direct
Jun 29, 2026	AUTL Autolus Therapeutics plc	Award(A) Restricted Share Units	31,667	-	-	Direct
Mar 5, 2026	JAZZ Jazz Pharmaceuticals plc	Tax Payment(F)	6,209	$188.69	$1,171,576	Direct
Feb 26, 2026	JAZZ Jazz Pharmaceuticals plc	Award(A)	14,822	-	$0	Direct
Jan 16, 2026	JAZZ Jazz Pharmaceuticals plc	Award(A)	11,699	-	$0	Direct
Jan 16, 2026	JAZZ Jazz Pharmaceuticals plc	Tax Payment(F)	4,140	$171.16	$708,602	Direct
Nov 17, 2025	JAZZ Jazz Pharmaceuticals plc	Sale(S)	7,159	$168.26	$1,204,573	Direct
Mar 10, 2025	JAZZ Jazz Pharmaceuticals plc	Sale(S)	2,403	$138.41	$332,605	Direct
Mar 7, 2025	JAZZ Jazz Pharmaceuticals plc	Sale(S)	5,532	$138.21	$764,578	Direct
Mar 7, 2025	JAZZ Jazz Pharmaceuticals plc	Sale(S)	1,548	$140.00	$216,720	Direct
Mar 5, 2025	JAZZ Jazz Pharmaceuticals plc	Disposition(D)	5,239	$138.95	$727,959	Direct
Feb 27, 2025	JAZZ Jazz Pharmaceuticals plc	Award(A)	17,718	-	-	Direct
Feb 27, 2025	JAZZ Jazz Pharmaceuticals plc	Award(A)	8,859	-	-	Direct

1-25 of 27 transactions

About Iannone Robert

Iannone Robert (SEC CIK 0001737329) files insider reports with the SEC as EVP, Global Head of R&D & CMO of Jazz Pharmaceuticals plc (JAZZ), Director of PLIANT THERAPEUTICS, INC. (PLRX) and Director of Autolus Therapeutics plc (AUTL).

Signal8 holds 14 ownership filings by Iannone Robert (2 Form 3, 12 Form 4), filed between Jan 22, 2025 and Aug 31, 2026. Those filings report 27 transactions, from Jan 17, 2025 to Aug 27, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Iannone Robert's filings is in LONDON.

Recent filings by Iannone Robert

Aug 27, 2026: Option exercise of JAZZ shares (Form 4, code M).
Aug 27, 2026: Open-market sales of JAZZ shares (6 lines, Form 4, code S).
Aug 27, 2026: Option exercises of JAZZ shares (3 lines, Form 4, code M).
Jul 9, 2026: Grant or award of PLRX derivative securities (Form 4, code A).
Jun 30, 2026: Tax withholding of JAZZ shares (Form 4, code F).

Other insiders filing for Jazz Pharmaceuticals plc (JAZZ)

GALA RENEE D, President & CEO
COZADD BRUCE C, Director
Patil Neena M, EVP & Chief Legal Officer
Henderson Mary Elizabeth, SVP, Technical Operations
Smith Mark Douglas, Director
RIEDEL NORBERT G, Director

How to read Form 4 transaction codes